The global digital diabetes management market size was estimated at USD 26.69 billion in 2023 and is projected to reach around USD 123.91 billion by 2032, at a CAGR of 18.60% from 2023 to 2032.
Key Points
- North America led the global market with the highest market share of 43% in 2022.
- Asia Pacific region is estimated to expand the fastest CAGR between 2023 and 2032.
- By Product, the services segment has held the largest market share of 49% in 2022.
- By Patient Type, the type 2 segment captured the biggest revenue share of 88% in 2022.
- By End User, the digital diabetes management segment is estimated to hold the highest market share of 37.5% in 2022.
The major industry leaders operating in the digital diabetes management are focusing on providing innovative products and introducing advanced technologies in this market. Recent increase in health awareness due to the pandemic has also supported the market to grow pertaining to the rapid steps take by the government towards health care facilities. The developing nations have contributed a small share as a result of lack of facilities.
Full Report is Ready | Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1783
Regional Snapshots
North America dominated the digital diabetes management market due to the increasing penetration of smart consumer products and innovation in artificial intelligence -based services and introduction of internet of things, big data, machine learning, and robotics in many nations. A tremendous growth is predicted in the Asia-Pacific region during the forecast period till 2030 as a result of the various products launched and which also hints the introduction of the next-generation BGM systems in the area. In the Asia Pacific, the countries like China and India have a high prevalence rate of diabetes, which is primarily because of the growing population, urbanization, and changes in the lifestyle. The rising patients suffering with diabetes, increasing health awareness, growing knowledge about the devices, huge number of undiagnosed individuals, and the increasing utilization of smartphones and tablets have propelled the acceptance of digital diabetes management options in the Asia Pacific region.
Report highlights
- By product, the smart insulin pump segment is expected to have the highest growth during the forecast period. Due to the launch of the Bluetooth enabled insulin pumps the market is expected to grow. These Bluetooth enabled insulin pumps provide access to data on the mobile phones.
- By type, the one diabetic patient segment will have a larger market share during the forecast period. The type one diabetic patients are highly dependent on the insulin. This is expected to create demand for the digital technologies.
- The hospital segment had the largest revenue in the recent years standard is expected to dominate the market during the forecast period. Digital technologies are used in remote patient monitoring. The integration of advanced software in the settings allows easy data management of these patients.
- By region, the European market is expected to have the largest market share during the forecast period. The presence of large number of competitors in this region and the introduction of good reimbursement rules and policies are expected to create a great demand in this market. Due to the province of diabetes in Germany, France, Italy and Spain the market is expected to witness a significant demand.
Digital Diabetes Management Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 18.60% |
| Market Size in 2023 | USD 26.69 Billion |
| Market Size by 2032 | USD 123.91 Billion |
| Largest Market | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, Device Type, Patient Type, App, End-Use, Geography |
Drivers
The increasing prevalence of diabetes is expected to help in increasing the demand for digital diabetes management devices and related services, which will also help in increasing the demand for the market. Diabetes is the main cause of death with 30% of loss of life expectancy due to the diagnosis of diabetes in majority of population
Restraints
The lack of the digital diabetes management devices in the developing nations and the lack of good reimbursement policies in the developing Nations is estimated to be the major drawback in the growth of this market and the lack of awareness of the advanced technology in the rural regions is also proving to be restraining factor for the growth of this digital diabetes management market.
Opportunities
The adoption of digital technologies offers the developers extraordinary opportunities to customize the care that diabetics receive and may help in reducing the need for conventional face-to face interactions. For instance, while patients with Type 2 diabetes may or may not need, or are less motivated, to use the latest CGM technology or the insulin pumps, there are many opportunities to increase the usage of digital tech for the local management of the patients.
Challenges
Improper protocols regarding the safety of information regarding patients is a major challenge faced by the market. Data safety is extremely important to maintain integrity and confidentiality in all the operations. Due to inappropriate flow of information and commands will certainly compromise the function of digital diabetes devices at use and it may put patients or users of these devices at the risk of other health problems
Read Also: Pharmaceutical Excipients Market Size, Report By 2030
Digital Diabetes Management Market Players
- Bayer AG
- Medtronic
- Roche Diagnostics
- Dexcom Inc. LifeScan Inc.
- AgaMatrix
- One Drop
- Abbott Laboratories
- Ascensia Diabetes Care
- ARKRAY Inc
- ACON Laboratories
- Insulet Corporation
- B. Braun Melsungen AG
- Tandem Diabetes Care
- Dottli
- Ypsomed Holding AG
- Becton Dickinson and Company
- Glooko Inc.
- DarioHealth
- Care innovations
Recent Developments
- Dexcom Inc., announced the launch of G6 CGM system in September 2020, in Turkey. The product launch has expanded its business in the international market.
- U.S. FDA approval which was granted to Abbott Laboratories in June 2020, for its CGM device, FreeStyle Libre 2, has supported the company in widening its product sector, and thus encouraging the company’s footprint in the universal market.
Segments covered in the report
By Product
- Devices
- Smart Glucose Meters
- Continuous Glucose Monitoring (CGM) Systems
- Smart Insulin Pens
- Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches
- Application
- Diabetes & Blood Glucose Tracking Apps
- Obesity & Diet Management Apps
- Data Management Software & Platforms
- Services
- Apps
- Software
By Device Type
- Handheld Devices
- Wearable Devices
By Patient Type
- Type 1
- Type 2
By App
- Digital Diabetes Management Apps
- Weight & Diet Management Apps
By End-Use
- Hospitals
- Home Settings
- Diagnostic Centers & Clinics
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/